Replies to post #16696 on Momenta Pharmaceuticals, Inc. (MNTA)

[alternatepatel]

floblu14

my estimate by 12/31 is $45+PPS if they are not taken out at $65

MNTA can be worth $65 but not anytime soon. Glatopa 40mg can add ~$1bn to valuation/cash in best case scenario. Big money is Humira biosimilar but difficult to value due to interchangeability (which won't be known at-least till FDA approval ~mid 2018 or later) & pending clarity on IP (70 patents expire between 2022-2034). BO is highly unlikely due to the very same issue IMO.

Let's see $30 first on Glatopa 40 approval.